Eculizumab, stock solution

仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用.Eculizumab （Anti-Complement C5） is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex （MAC）. Eculizumab has the potential for haemolysis research. Eculizumab （Anti-Human C5, Humanized Antibody） 是一种针对补体 C5 （complement C5） 的长效人源化单克隆抗体。Eculizumab 抑制 C5 裂解为 C5a 和 C5b，因此抑制末端补体系统的部署，包括膜攻击复合物 （MAC） 的形成。Eculizumab 具有用于溶血研究的潜力